primary biliary cholangitis Archives -

Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis

Ipsen places €480m bet on Genfit’s liver drug elafibranor

https://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/

Regulator warns of death risk in patients on higher than recommended dose.

Intercept shares dive after FDA safety alert on liver drug

https://pharmaphorum.com/news/intercept-shares-fda-safety/

NHS patients to get access to drug in PBC.

Intercept’s liver drug gets green light from NICE

https://pharmaphorum.com/news/intercepts-liver-drug-nice/

Sales forecast to reach $2.6 billion in 2020.

EU regulator recommends Intercept’s potential liver blockbuster

https://pharmaphorum.com/news/eu-regulators-back-intercepts-potential-liver-blockbuster/

primary biliary cholangitis